Mifepristone: The multifaceted antihormone

Journal of Drug Evaluation

Volumn 1, Issue 5, 2003, Pages 149-175

  Hapangama, Dharani K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ANTIGESTAGEN; AROMATASE INHIBITOR; ATAMESTANE; CYCLOOXYGENASE 2; DEXAMETHASONE; DROLOXIFENE; ESTRADIOL; GEMEPROST; GESTAGEN; GONADORELIN DERIVATIVE; LEUKEMIA INHIBITORY FACTOR; LEVONORGESTREL; MALE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE; METHOTREXATE; MIFEPRISTONE; MISOPROSTOL; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NALOXONE; ONAPRISTONE; ORAL CONTRACEPTIVE AGENT; PREDNISOLONE; PROGESTERONE; PROGESTERONE RECEPTOR; PROSTAGLANDIN; PROSTAGLANDIN F2 ALPHA; TAMOXIFEN; UNINDEXED DRUG;

ABDOMINAL PAIN; ALZHEIMER DISEASE; AMENORRHEA; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; BREAKTHROUGH BLEEDING; BREAST CANCER; BURN; CUSHING DISEASE; CUSHING SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; ECTOPIC PREGNANCY; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; FERTILIZATION IN VITRO; FETUS MALFORMATION; FOLLICULAR PHASE; HORMONE RESPONSIVE ELEMENT; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LABOR INDUCTION; LEIOMYOMA; LOW DRUG DOSE; LUTEAL PHASE; MAJOR DEPRESSION; MENINGIOMA; MENOPAUSAL SYNDROME; MENSTRUAL IRREGULARITY; METRORRHAGIA; MULTIPLE DRUG DOSE; NONHUMAN; OPEN ANGLE GLAUCOMA; OVARY CYCLE; OVARY HYPERSTIMULATION; PREGNANCY TERMINATION; REVIEW; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; STRUCTURE ACTIVITY RELATION; TERATOGENICITY; THERAPEUTIC ABORTION; UTERINE CERVIX RIPENING; VAGINA BLEEDING;

EID: 1542329211     PISSN: 14791137     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (289)

1. Cadepond F, Ulmann A, Baulieu EE. RU 486 (Mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997;48:129-56
2. Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 2000;65:571-7
3. Spencer TE, Bazer FW. Biology of progesterone action during pregnancy recognition and maintenance of pregnancy. Front Biosci 2002;7:d1879-97
4. Corner GW, Allen WM. Physiology of the corpus luteum. II. Production of a special uterine reaction (progestational proliferation) by extracts of the corpus luteum. Am J Physiol 1929;88:326-9
5. Pincus G. The Control of Fertility. New York: Academic Press, 1965:128-38
6. O'Malley BW, McGuire WL, Kohler PO, et al. Studies on the mechanism of steroid hormone regulation of synthesis of specific proteins. Recent Prog Horm Res 1969; 25:105-51
7. Sherman MR, Corval PL, O'Mallay BW. Progesterone binding components of chick oviduct. I. Preliminary characterization of cytoplasmic components. J Biol Chem 1970;245:6085-96
8. Teutsch G. Analogues of RU 486 for the mapping of the progestin receptor: synthetic and structural aspects. In Baulieu EE, Segal SJ, eds. The Antiprogestin Steroid RU 486 and Human Fertility Control. New York: Plenum Press, 1985:27-47
9. Belanger A, Philibert D, Teutsch G. Regio- and stereo-specific synthesis of 11β- substituted 19-norSteroids. Steroids 1981;37:361-82
10. Philibert D, Deraedt R, Teutsch G. RU 486: a potent antiglucocorticoid in vivo. Presented at the Program of the VIII International Congress of Pharmacology, Tokyo, Japan, 1981:abstr. 1463
11. Herrman W, Wyss R, Riondel A. The effects of an antiprogesterone steroid on women: interruption of the menstrual cycle and of early pregnancy (translation). C R Acad Sci III 1982;294:933-8
12. Evans RM. The steroid and thyroid receptor super-family. Science 1988;240:889-95
13. Baulieu EE. Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science 1989;245:1351-7
14. Garcia T, Benhamou B, Gofflo D, et al. Switching agonistic, antagonistic and mixed transcriptional responses to 11-beta-substituted progestins by mutation of the progesterone receptor. Mol Endocrinol 1992;6:2071-8
15. Spitz IM, Bardin CW. Clinical pharmacology of RU 486 - an antiprogestin and antiglucocorticoid. Contraception 1993;48:403-44
16. Heikinheimo O, Haukkamaa M, Lahteenmaki P. Distribution of RU 486 and its demethylated metabolites in humans. J Clin Endocrinol Metab 1987;68:270-75
17. Steingold KA, Matt DW, Dua L, et al. Orosomucoid in human pregnancy serum diminishes bioavailability of the progesterone antagonist RU 486 in rats. Am J Obstet Gynecol 1990;162:523-4
18. Lahteenmaki P, Heikinheimo O, Croxatto H, et al. Pharmacokinetics and metabolism of RU 486. J Steroid Biochem 1987;27:859-63
19. Tremblay D, Busigny M, Bonnat C. Experimental demonstration in the rat of the role played by human α-1-glycoprotein (HAAG) in the nonlinearity of RU 486 pharmacokinetics in women. In α-1-Acid Glycoprotein: Genetics, Biochemistry, Physiological Function and Pharmacology. New York: Alan R. Liss, 1989
20. Deraedt R, Bonnat C, Busigny M, et al. Pharmacokinetics of RU 486. In Baulieu EE, Segal SJ, eds. The Antiprogestin Steroid RU 486 and Human Fertility Control. New York: Plenum Press, 1985:103-22
21. Shi Y, Ye Z, He C, et al. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception 1993;48:133-49
22. Sakar NN. Mifepristone: bio-availability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol 2002;101:113-20
23. Bertagna X, Escourolle H, Pinquier JL, et al. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effects with no evidence of peripheral cortisol deprivation. J Clin Endocrinol Metab 1994;78: 375-80
24. Gaillard RC, Riondel A, Muller AF, et al. RU 486: a steroid with antiglucacosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Proc Natl Acad Sci USA 1984;81:3879-82
25. Laue L, Lotze MT, Chrousos GP, et al. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological and hormonal aspects. J Clin Endocrinol Metab 1990;71:1474-80
26. Chrousos GP, Laue L, Nieman LK, et al. Glucocorticoids and glucocorticoid antagonists: lessons from RU 486. Kidney Int Suppl 1988;26:S18-23
27. Heikinheimo O. Pharmacokinetics of the antiprogestin RU 486 in women during multiple dose administration. J Steroid Biochem 1989;32:21-5
28. Lamberts SW, Koper JW, de Jong FH. The endocrine effects of long-term treatment with mifepristone. J Clin Endocrinol Metab 1991;73:189-91
29. Heikinheimo O, Ratna S, Grunberg S, et al. Alterations in sex steroids and gonadotrophins in post-menopausal women subsequent to long-term mifepristone administration. Steroids 2000;65:831-6
30. Grunberg SM, Weiss MH, Spitz IM, et al. Long-term treatment with the oral anti-progestational agent mifepristone (RU 486). In: Salmon SE, ed. Adjuvant Therapy of Cancer VII. Philadelphia, PA: Lippincott Company, 1993:55-62
31. Hill NC, Selinger M, Ferguson J, et al. Trans-placental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy. Hum Reprod 1991;6:458-62
32. Doherty P. Medical abortion. Br Med J 1992;304:573
33. Jost A. New data on the hormonal requirement of the pregnant rabbit: partial pregnancies and fetal abnormalities after treatment with a hormonal antagonist given at a sub-abortive dosage. C R Acad Sci III 1986;303:281-4
34. Wolf JP, Chillik CF, Dubois C, et al. Tolerance of perinidatory primate embryos to RU 486. Contraception 1990;41:85-92
35. Henrion R. RU 486 abortions. Nature 1989;338:110
36. Sitruk-Ware R, Davey A, Sakiz E. Fetal malformation and failed medical termination of pregnancy. Lancet 1998;352:323
37. Lim BH, Lees DAR, Bjornsson S, et al. Normal development after exposure to mifepristone in early pregnancy. Lancet 1990;336:257-8
38. Mani SK, Blaustein JD, Allen JM, et al. Inhibition of rat sexual behaviour by antisense oligonucleotides to the progesterone receptor. Endocrinology 1994;135:1409-14
39. Mani SK, Allen JM, Clark JH, et al. Convergent pathways for steroid hormone- and neurotransmitter- induced rat sexual behaviour. Science 1994;245:1246-9
40. Tibbetts TA, DeMayo F, Rich S, et al. Progesterone receptors in the thymus are required for thymic involution during pregnancy and for normal fertility. Proc Natl Acad Sci USA 1999;96:12021-6
41. Allen WM, Wintersteiner OS. Crystalline progestin. Science 1934;80:190-91
42. Butenandt A, Dannenbaum H. Uber androsterone: isolierung eines neuen physiologisch unwirksamen steroiderivatives ans mannernarn, seine verknutsung mit dehydroandrosterone und androsterone bin beitrag vurk constitution des androsterone. Z Physiol Chem 1934;229:192-208
43. Hartmann M, Wettstein A. Zur kenntnis der corpusluteum hormone. Helv Chim Acta 1934;17:1365-72
44. Lieberman S, Erlanger BF, Beiser SM. Steroid protein conjugates: their chemical, immunochemical and endocrinological properties. In Pincus G, ed. Recent Progress in Hormone Research. Volume XV. New York: Academic Press, 1959
45. Miligrom E, Baulieu EE. Progesterone in uterus and plasma. I. Binding in rat uterus 105 000 supernatant. Endocrinology 1970;87:276-86
46. Csapo AI, Pulkkinen M. Indispensibility of the human corpus luteum in the maintenance of early pregnancy. Obstet Gynecol Surv 1978;33:69-81
47. Shymala G, Conneely OM, O'Malley BW. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995;9:2266-78
48. Conneely OM, Mulac-Jericevic B, Lydon JP, et al. Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice. Mol Cell Endocrinol 2001;179:97-103
49. Walters MR, Clark JH. Cytosol progesterone receptor of the rat uterus: assay and receptor characteristics. J Steroid Biochem 1977;8:1137-44
50. Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol and estriol on hormone-responsive breast cancer in long-term tissue culture. Cancer Res 1977;37: 1901-7
51. Rousseau GG, Baxter JD, Higgins SJ, et al. Steroid-induced nuclear binding of glucocorticoid receptors in intact hepatoma cells. J Mol Biol 1973;79:539-44
52. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301
53. Kumar V, Green S, Stack G, et al. Functional domains of the human estrogen receptor. Cell 1987;51:941-51
54. Carson-Jurica MA, Schrader WT, O'Malley BW. Steroid-receptor family: structure and functions. Endocr Rev 1990;11:201-20
55. Tora L, Gronemeyer H, Turcotte B, et al. The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature 1988;333:185-9
56. Sartorius CA, Melville MY, Hovland AR, et al. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 1994;8:1347-60
57. Freedman LP. Anatomy of the steroid receptor Zinc finger region. Endocr Rev 1992;13:129-45
58. Peterson CM. Estrogen and progesterone receptors: an overview from the year 2000. J Soc Gynecol Invest 2000; 7(Suppl. 1):3-6
59. Conneely OM, Lydon JP, De Mayo F, et al. Reproductive functions of the progesterone receptor. J Soc Gynecol Invest 2000;7(Suppl. 1):24-32
60. Webster NJG, Green S, Jim J-R, et al. The hormone-binding remains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 1988;54:199-207
61. Fawell SE, Lees JA, White R, et al. Characterization and co-localization of steroid binding and dimerization activities in the mouse oestrogen receptor. Cell 1990;60: 953-62
62. Vegeto E, Allan GF, Schrader WT, et al. The mechanism of RU 486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 1992;69:703-13
63. Lanz RB, Rusconi S. A conserved carboxy-terminal subdomain is important for ligand interpretation and transactivation by nuclear receptors. Endocrinology 1994;135: 2183-95
64. Laumas KR, Farooq A. The uptake in vivo of [1,2-3H]-progesterone by the brain and genital tract of the rat. J Endocrinol 1966;36:95-6
65. Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990;9:1603-14
66. Chalbos D, Galtier F. Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription. J Biol Chem 1990;269:23007-12
67. Shyamala G, Schneider W, Schott D. Developmental regulation of murine mammary progesterone receptor gene expression. Endocrinology 1990;126:2882-9
68. Duffy DM, Wells TR, Haluska GJ, et al. The ratio of progesterone receptor isoforms changes in the monkey corpus luteum during the luteal phase of the menstrual cycle. Biol Reprod 1997;57:693-9
69. Mangal RK, Wiehle RD, Poindexter AN III, et al. Differential expression of uterine progesterone receptor A and B forms during the menstrual cycle. J Steroid Biochem Mol Biol 1997;63:195-202
70. Graham JD, Yeates C, Balleine RL, et al. Progesterone receptor A and B protein expression in human breast cancer. J Steroid Biochem Mol Biol 1996;56:93-8
71. Vegeto E, Shabaz MM, Wen DX, et al. Human progesterone receptor A type is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993;7:1244-55
72. McDonnell DP, Shahbaz MM, Vegeto E, et al. The human progesterone receptor A form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. J Steroid Biochem Mol Biol 1994; 48:425-32
73. McDonnell DP, Goldman ME. RU 486 exerts antioestrogenic activities through a novel progesterone receptor A form mediated mechanism. J Biol Chem 1994;269: 11945-9
74. Saatcioglu F, Claret K, Karin M. Negative transcriptional regulation by nuclear receptors. Semin Cancer Biol 1994; 5:347-59
75. Lydon JP, DeMayo FJ, Funk CR, et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995;9:2266-78
76. Cheung J, Smith DF. Molecular chaperone interactions with steroid receptors: an update. Mol Endocrinol 2000;14:939-46
77. Baulieu EE, Catelli MG. Steroid hormone receptors and heat shock protein Mr 90 000 (hsp90): a functional interaction? In Pardue ML, Feramisco JR, Lindquist S, eds. Stress-Induced Proteins. New York: Liss, 1989:203-19
78. Baulieu EE, Binart N, Cadepond F. Do receptor-associated nuclear proteins explain earliest steps of steroid hormone function? In Carlstedt-Duke J, Eriksson H, Gustafsson JA, eds. The Steroid/Thyroid Hormone Receptor Family and Gene Regulation. Basel: Birhauser Verlag, 1989:301-18
79. Lebeau MC, Binart N, Cadepond F, et al. Steroid-receptor-associated proteins: heat shock protein 90 and p59 immunophilin. In Moudgil VK, ed. Steroid Hormone Receptors: Basic and Clinical Aspects. Boston, MA: Birkhauser, 1993:261-80
80. Bourgeois S, Mester J, Baulieu EE. DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU 486. EMBO J 1984;3:751-5
81. Allan GF, Leng XH, Tsai SY, et al. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 1992;267:19513-20
82. Tsai SY, Carlstedt-Duke J, Weigel NL, et al. Molecular interactions of steroid receptor with its enhancer element: evidence for receptor dimer formation. Cell 1988;57: 1147-54
83. Edwards DP, Weigel NL, Nordeen SK, et al. Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists. Breast Cancer Res Treat 1993;27:41-56
84. Weigel NL. Overview and background: mechanism of action of antiprogestins. In Donaldson MS, Dorflinger L, Brown SS, et al., eds. Clinical Applications of Mifepristone (RU 486) and Other Anti-Progestins. Washington, DC: National Academy Press, 1993:120-38
85. Weigel NL. Receptor phosphorylation. In Tsai MJ, O'Malley BW, eds. Mechanism of Steroid Hormone Regulation of Gene Transcription. Austin, TX: R.G. Landes Co., 1994:93-110
86. Beato M, Chalepakis G, Schauer M, et al. DNA regulatory elements for steroid hormones. J Steroid Biochem 1989; 32:737-47
87. Beato M, Chavez S, Truss M. Transcriptional regulation by steroid hormones. Steroids 1996;61:240-51
88. Rowen BG, O'Malley BW. Progesterone receptor co-activators. Steroids 2000;65:545-9
89. Truss M, Beato M. Steroid receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 1993;14:459-79
90. Truss M, Bartsch J, Beato M. Antiprogesterones prevent progesterone receptor binding to hormone response elements in vivo. Proc Natl Acad Sci USA 1994;91:11333-7
91. Meyer MC, Pornon A, Ji J. Agonist and antagonist activities of RU 486 on the functions of the human progesterone receptor. EMBO J 1990;9:3923-32
92. Bain DL, Franden MA, McManaman JL, et al. The N-terminal region of the human progesterone A-receptor. J Biol Chem 2000;275:7313-20
93. Beck CA, Weigel NL, Edwards DP. Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptor. Mol Endocrinol 1992;6:607-20
94. Edwards DP, Leonhardt SA, Gass-Handel E. Novel mechanisms of progesterone antagonism and progesterone receptor. J Soc Gynecol Invest 2000;7(Suppl. 1):S22-4.
95. Edwards DP, Boonyaratanakornkit V. Progesterone receptor activation of transduction signalling pathways through SH3 domain interactions. Presented at Second International Symposium on Progestins, Progesterone Receptor Modulators and Progesterone Antagonists, Siena, Italy, November 2002
96. Revelli A, Massobrio M, Tesarik J. Nongenomic actions of steroid hormones in reproductive tissues. Endocr Rev 1998;19:3-17
97. Machelon V, Nome F, Grosse B, et al. Progesterone triggers rapid transmembrane calcium influx and/or calcium mobilization from endoplasmic reticulum, via a pertussis-insensitive G-protein in granulosa cells in relation to luteinization process. J Cell Biochem 1996;61:619-28
98. Sadler SE, Maller JL. Inhibition of Xenopus laevis adenylate cyclase by progesterone: a novel mechanism of action. Adv Cyclic Nucleotide Protein Phosphoryl Res 1985;19:179-94
99. Bray C, Publicover S, Barratt CR. Progesterone interaction with sperm plasma membrane, calcium influx and induction of the acrosomal reaction. Reprod Med Rev 1999;7:81-93
100. Hsueh AJW, Peck EJ Jr, Clark JH. Progesterone antagonism of the estrogen receptor and estrogen-induced uterine growth. Nature 1975;254:337-9
101. Katzenellenbogen BS. Dynamics of steroid receptor action. Annu Rev Physiol 1980;42:17-35
102. Tseng L, Gurpide E. Induction of human endometrial estradiol dehydrogenase by progestins. Endocrinology 1975;97:825-33
103. Bhakoo HS, Katzenellenbogen BS. Progesterone modulation of estrogen-stimulated uterine biosynthetic events and estrogen receptor levels. Mol Cell Endocrinol 1977;8:121-34
104. Kirkland JL, Murthy L, Stancel GM. Progesterone inhibits the estrogen-induced expression of c-fos messenger ribonucleic acid in the uterus. Endocrinology 1992;130:3223-30
105. Elger W, Bartley J, Schneider B, et al. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000;65: 713-23
106. Suzuki T, Sasano H, Kimura N, et al. Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroidogenic enzymes. Hum Reprod 1994;9:1589-95
107. Schenken RS, Werlin LB, Williams RF, et al. Histological and hormonal documentation of the luteinized unruptured follicle syndrome. Am J Obstet Gynecol 1986;154: 839-47
108. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18:502-19
109. Philibert D. RU 38486: an original multifaceted antihormone in vivo. In Agarwal MK, ed. Adrenal Steroid Antagonism. Berlin: Walter de Gruyer & Co., 1984:77-101
110. Skafar DF. Differences in the binding mechanism of RU 486 and progesterone to the progesterone receptor. Biochemistry 1991;30:10829-32
111. Healy DL, Chrousos GP, Schulte HM, et al. Pituitary and adrenal responses to the antiprogesterone and antiglucacorticoid steroid RU 486 in primates. J Clin Endocrinol Metab 1983;57:863-5
112. Healy DL, Chrousos GP, Schulte HM, et al. Increased adrenocorticotropin, cortisol and arginine vasopressin secretion in primates after the antiglucocorticoid steroid RU 486: dose-response relationship. J Clin Endocrinol Metab 1985;60:1-4
113. Bertagna X, Bertagna C, Luton JP, et al. The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 1984;59:25-8
114. Gaillard RC, Riondel A, Muller AF, et al. RU 486: a steroid with antiglucacosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Proc Natl Acad Sci USA 1984;81: 3879-82
115. Weigel NL, Beck CA, Estes PA. Ligands induce conformational changes in the carboxy-terminus progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol Endocrinol 1992;6: 1585-97
116. Benhamou B, Garcia T, Lerouge T, et al. A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science 1992;255:206-9
117. Baulieu EE. RU 486 - a decade on today and tomorrow. In Donaldson MS, Dorflinger L, Brown SS, et al., eds. Clinical Applications of Mifepristone RU 486 and Other Antiprogestins. Washington, DC: National Academic Press, 1993:71-220
118. Gronemeyer H, Benhamou B, Berry M, et al. Mechanisms of antihormone action. J Steroid Biochem Mol Biol 1992;41:217-21
119. Baulieu EE. RU 486 (an anti-steroid hormone) receptor structure and heat shock protein mol. Wt 90 000 (hsp 90). Hum Reprod 1988;3:541-7
120. El-Ashry-Stowers D, Onate SA, Nordeen SK, et al. Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 1989;3:1545-58
121. DeMarzo AM, Onate SA, Nordeen SK, et al. Effects of the steroid antagonist RU 486 on dimerization of the human progesterone receptor. Biochemistry 1992;31: 10491-501
122. Gass EK, Leonhardt SA, Nordeen SK, et al. The antagonist RU 486 and ZK 98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation. Endocrinology 1998;139:1905-19
123. Beck CA, Estes PA, Bona BJ, et al. The steroid antagonist RU 486 exerts different effects on the glucocorticoid and progesterone receptors. Endocrinology 1993;133: 728-40
124. Leonhardt SA, Edwards DP. Mechanism of action of progesterone antagonists. Exp Biol Med 2002;227:969-80
125. Edwards DP. Co-regulatory proteins in nuclear hormone receptor action. Vitam Horm 1999;55:165-218
126. Jackson TA, Richer JK, David L, et al. The partial-agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain binding co-activator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997;11:693-705
127. Smith CL, Nawaz Z, O'Malley BW. Co-activator and co-repressor regulation of the agonist/antagonist activity of the mixed antioestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11:657-66
128. Wolf JP, Hsiu JG, Anderson TL. Non-competitive anti-estrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrated monkeys. Fertil Steril 1989;52:1055-60
129. Van Uem JF, Hsiu JG, Chillik CF. Contraceptive potentials of RU 486 by ovulation inhibition. I. Pituitary versus ovarian action with blockade of estrogen-induced endometrial proliferation. Contraception 1989;35: 433-8
130. Brenner RM, Slayden OD. Antiprogestin action in the non-human primate reproductive tract. Presented at the Second International Symposium on Progestins, Progesterone Receptor Modulators and Progesterone Antagonists, Siena, Italy, November 2002
131. Beck CA, Weigel NL, Moyer ML, et al. The progesterone antagonist RU 486 acquires agonist activity upon stimulation of cAMP signalling pathway. Proc Natl Acad Sci USA 1993;90:4441-5
132. Nordeen SK, Bona BJ, Beck CA, et al. The two faces of a steroid antagonist: when an antagonist isn't. Steroids 1995;60:97-104
133. Stuenkel CA, Garzo VG, Morris S, et al. Effects of antiprogesterone RU 486 in early follicular phase of the menstrual cycle. Fertil Steril 1990;53:642-6
134. Shoupe D, Mishell DR Jr, Lahteenmaki P, et al. Effects of the antiprogesterone RU 486 in normal women. I. Single dose administration in the mid-luteal phase. Am J Obstet Gynecol 1987;157:1415-20
135. Permezel JM, Lenton EA, Roberts I, et al. Acute effects of progesterone and the antiprogestin RU486 on gonadotropin secretion in the follicular phase of the menstrual cycle. J Clin Endocrinol Metab 1988;68: 960-65
136. Drouin J, Labrie F. Interactions between 17β estradiol and progesterone in the control of luteinizing hormone and follicle-stimulating hormone release in rat anterior pituitary cells in culture. Endocrinology 1981;108:52-7
137. Luukkainen T, Heikinheimo O, Haukkamaa M, et al. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. Fertil Steril 1988;49:961-3
138. Nieman LK. The use of antiprogestins in the reproductive cycle. In Donaldson MS, Dorflinger L, Brown SS, et al., eds. Clinical Applications of Mifepristone RU 486 and Other Antiprogestins. Washington, DC: National Academic Press, 1993:139-47
139. Liu JH, Garzo G, Morris S, et al. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. J Clin Endocrinol Metab 1987;65:1135-40
140. Batista MC, Cartledge TP, Zellmer AW, et al. Evidence for a critical role of progesterone in the regulation of the midcycle gonadotropin surge and ovulation. J Clin Endocrinol Metab 1992;74:565-70
141. Baird DT, Thong KJ, Hall C, et al. Failure of oestrogen-induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days. Hum Reprod 1995;10:2270-76
142. Marions L, Hultenby K, Lindell I, et al. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol 2002;100:65-71
143. Critchley HOD, Baird DT. Antigestrogen RU 486 increases LH secretion in the luteal phase of the menstrual cycle. J Endocrinol 1988;18 (Suppl. 1):abstr. 95
144. Garzo VG, Liu J, Ulmann A, et al. Effects of an antiprogesterone (RU 486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle. J Clin Endocrinol Metab 1988;66:508-17
145. Shoupe D, Mishell DR Jr, Fossum G, et al. Antiprogestin treatment decreases midluteal luteinizing hormone pulse amplitude and primarily exerts a pituitary inhibition. Am J Obstet Gynecol 1990;163:1982-5.
146. Schaison G, George M, Lestrat N, et al. Effects of the antiprogesterone steroid RU 486 during the mid-luteal phase in normal women. J Clin Endocrinol Metab 1985;61:484-9
147. Greene KE, Kettle LM, Yen SSC. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of the luteal phase of the menstrual cycle: a contraceptive potential. Fertil Steril 1992;58:338-42
148. Brenner RM, Slayden OD. Oestrogen action in the endometrium and oviduct of rhesus monkeys during RU486 treatment. Hum Reprod 1994;9(Suppl. 1):82-97
149. Slayden OD, Brenner RM. RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta). J Clin Endocrinol Metab 1994;78:440-8
150. Swahn M-L, Johannisson E, Daniore V, et al. The effect of RU 486 administration during the proliferative and secretory phase of the cycle on the bleeding pattern hormonal parameters and endometrium. Hum Reprod 1988;3:915-21
151. Swahn M-L, Bygdeman M, Xing S, et al. The effects of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Hum Reprod 1990;5:402-8
152. Gemzell-Danielsson K, Svalander P, Swahn, M-L, et al. Effects of a single post-ovulatory dose of RU 486 on endometrial maturation in the implantation phase. Hum Reprod 1994;9:2398-404
153. Cameron ST, Critchley HOD, Buckley CH, et al. The effects of post-ovulatory administration of onapristone on the development of a secretory endometrium. Hum Reprod 1996;11:40-49
154. Berthois Y, Salat-Baroux J, Cornet D, et al. A multi-parametric analysis of endometrial oestrogen and progesterone receptors after post-ovulatory administration of mifepristone. Fertil Steril 1991;55:547-54
155. Cameron ST, Critchley HOD, Buckley CH, et al. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Fertil Steril 1997;67:1046-53
156. Casey ML, Hemsell DL, Johnston JM, et al. NAD-dependent 15-hydroxyprostaglandin dehydrogenase activity in human endometrium. Prostaglandins 1980;19: 115-22
157. Greenland KJ, Jantke I, Jennatschke S, et al. The human NAD+ dependent 15-hydroxyprostaglandin dehydrogenase gene promoter is controlled by Ets and activating protein-1 transcription factors and progesterone. Endocrinology 2000;141:581-97
158. Burton KA, Hillier SG, Habib FK, et al. Spatial and temporal distribution of the androgen receptor in human endometrium. J Reprod Fertil 2000;25:abstr. 113
159. Slayden OD, Nayak NR, Burton KA, et al. Progesterone antagonists increase the androgen receptor expression in the rhesus macaque in human endometrium. J Clin Endocrinol Metab 2001;86:2668-79
160. Gemzell-Danielsson, K, Hamberg M. The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid PGF2α concentrations. Hum Reprod 1994;9:1626-30
161. Marions L, Danielsson KG. Expression of cyclo-oxygenase in human endometrium during the implantation period. Mol Hum Reprod 1999;5:961-5
162. Maentausta O, Svalander P, Gemzell-Danielsson K, et al. The effects of an antiprogestin, mifepristone, and an anti-estrogen, tamoxifen, on endometrial 17β-hydroxysteroid dehydrogenase and progestin and estrogen receptor during the luteal phase of the menstrual cycle: an immunohistochemical study. J Clin Endocrinol Metab 1993;77:913-18
163. Johannisson E, Oberholzer M, Swahn M-L, et al. Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486. Contraception 1988;39:103-17
164. Cheng L, Kelly RW, Thong KJ, et al. The effects of mifepristone (RU 486) on prostaglandin dehydrogenase in decidual and chorionic tissue in early pregnancy. Hum Reprod 1993;8:705-9
165. Batista MC, Cartledge TP, Zellmer AW, et al. Delayed endometrial maturation induced by daily administration of the antiprogesterone RU 486: a potential new contraceptive strategy. Am J Obstet Gynecol 1992;167: 60-65
166. Croxatto HB, Salvatierra AM, Croxatto HD, et al. Effects of continuous treatment with low-dose mifepristone throughout one menstrual cycle. Hum Reprod 1993; 8:201-7
167. Gemzell Danielsson K, Swahn ML, Bygdeman M. The effect of various doses of mifepristone on endometrial leukaemia inhibitory factor expression in the midluteal phase - an immunohistochemical study. Hum Reprod 1997;12:1293-7
168. Gemzell Danielsson K, Westlund P, Johannisson E, et al. Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum Reprod 1996;11:256-64
169. Gravanis A, Schaison G, George M, et al. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J Clin Endocrinol Metab 1985;60:156-63
170. Baldi E, Krausz C, Luconi M, et al. Actions of progesterone on human sperm: a model for non-genomic effects of steroids. J Steroid Biochem Mol Biol 2000;53: 199-203
171. Spitz IM, Van Look PFA, Bennink HJTC. The use of progesterone antagonists and progesterone receptor modulators in contraception. Steroids 2000;65:817-23
172. Yang YQ, Wu JT. RU 486 interferes with egg transport and retards the in vivo and in vitro development of mouse embryos. Contraception 1990;41:551-6
173. Yang J, Serres C, Philibert D, et al. Progesterone and RU 486: opposing effects on human sperm. Proc Natl Acad Sci USA 1994;91:529-33
174. Couzinet B, Le Strat N, Silvestre L, et al. Late luteal administration of the antiprogesterone RU 486 in normal women: effects on the menstrual cycle events and fertility control in a long-term study. Fertil Steril 1990;54:1039-44
175. Glasier AF, Smith KB, Cheng L, et al. An international study on the acceptability of a once-a-month pill. Hum Reprod 1999;14:3018-22
176. World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial. Hum Reprod 1995;10:308-14
177. Dubois C, Ulmann A, Baulieu E-E. Contragestion with late luteal administration of RU 486 (Mifepristone). Fertil Steril 1988;50:593-6
178. Swahn M-L, Bygdeman M, Jun-kang C, et al. Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol. Hum Reprod 1999;14:485-8
179. Gemzell-Danielsson K, Svalander P, Swahn M-L, et al. Early luteal phase treatment with RU 486 for fertility regulation. Hum Reprod 1993;8:870-73
180. Hapangama DK, Brown, A, Glasier AF, et al. Feasibility of administering mifepristone as a once a month pill. Hum Reprod 2001;16:1145-50
181. Rimmer C, Horga M, Cerar V, et al. Do women want a once-a-month pill? Hum Reprod 1992;7:608-11
182. Croxatto HB, Salvatierra AM, Romero C, et al. Late luteal phase administration of RU 486 for three successive cycles does not disrupt bleeding pattern or ovulation. J Clin Endocrinol Metab 1987;157:1415-20
183. Ulmann A, Dubois C, Philibert D. Fertility control with RU 486. Horm Res 1987;28:274-8
184. Swahn M-L, Gemzelle-Danielsson K, Bygdeman M. Contraception with antiprogesterone. In Glasier A, ed. Balliere's Clinical Obstetrics and Gynaecology: Contraception. Oxford: Balliere Tindall, 1996:43-55
185. Glasier AF, Thong K.J, Dewar M, et al. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency post-coital contraception. N Engl J Med 1992;327:1041-4
186. Webb AMC, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol and mifepristone (RU 486) in oral post-coital contraception. Br Med J 1992;305:927-31
187. World Health Organization Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet 1999;353:697-702
188. Ashok PW, Wagaarachchi PT, Flett GM, et al. Mifepristone as late post-coital contraception. Hum Reprod 2001;16:72-5
189. Marions L, Daniellson KG, Swahn ML, et al. Contraceptive efficacy of low doses of mifepristone. Fertil Steril 1998;70:813-16
190. Spitz IM, Croxatto HB, Salvatierra AM, et al. Response to intermittent RU 486 in women. Fertil Steril 1993;59: 971-5
191. Cheng X, Xiao B. Effect of once weekly administration of mifepristone on ovarian function in normal women. Contraception 1997;56:175-80
192. Ledger WL, Sweeting VM, Hillier H. Inhibition of ovulation by low-dose mifepristone (RU 486). Hum Reprod 1992;7:945-50
193. Croxatto HB, Kovacs L, Massai R, et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod 1998;13:793-8
194. Brown A, Cheng L, Lin S, et al. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomised control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63-70
195. Borman SM, Chwalisz K, Stouffer RL, et al. Oocyte function and perimplantation embryogenesis following chronic low-dose antiprogestin in macaques. Presented at the Second International Symposium on Progestins, Progesterone Receptor Modulators and Progesterone Antagonists, Siena, Italy, November 2002
196. Narvekar N, Critchley HOD, Lin S, et al. Presented at the Second International Symposium on Progestins, Progesterone Receptor Modulators and Progesterone Antagonists, Siena, Italy, November 2002
197. Den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use and hormone replacement therapy use. Contraception 1999;59:357-62
198. Baird DT, Brown A, Critchley HOD, et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18:61-8
199. Croxatto HB, Massai MR, Salvatierra AM, et al. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters. Contraception 1996;54:79-86
200. Croxatto HB, Salvatierra AM, Fuentealba B, et al. Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women. Hum Reprod 1998;13:3297-302
201. Elliott CL, Brennand JE, Calder AA. The effects of mifepristone on cervical ripening and labour induction in primigravidae. Obstet Gynecol 1998;92:804-9
202. Wing DA, Fassett MJ, Mishell DR Jr. Mifepristone for preinduction cervical ripening beyond 41 weeks' gestation: a randomized controlled trial. Obstet Gynecol 2000; 96:543-8
203. Neilson JP. Mifepristone for induction of labour. Cochrane Database Syst Rev 2000;4:CD002865
204. Giacalone PL, Daures JP, Faure JM, et al. The effects of mifepristone on uterine sensitivity to oxytocin and fetal heart rate pattern. Eur J Obstet Gynecol Reprod Biol 2001;97:30-34
205. Norman JE, Kelly RW, Baird DT. Uterine activity and decidual prostaglandin production in women in early pregnancy in response to mifepristone with or without indomethacin in vivo. Hum Reprod 1991;6:740-44
206. Norman JE, Wen Xuan W, Kelly RW, et al. Effects of mifepristone in vivo on decidual prostaglandin synthesis and metabolism. Contraception 1991;44:89-98
207. Anonymous. UK multicentre trial - final results. The efficacy and the tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days' gestation. Contraception 1997;55:1-5
208. Ulmann A, Silvestre L, Chemama L. Medical termination of pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Acta Obstet Gynecol Scand 1992;71:278-83
209. Bartley J, Brown A, Elton R, et al. Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days' gestation. Hum Reprod 2001;16:2098-102
210. Baird DT, Succhareon N, Thong KJ. Randomised trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Hum Reprod 1995;10:1521-7
211. Spitz IM, Bardin CW, Benton L, et al. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241-7
212. Bartley J, Tong S, Everington D, et al. Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. Contraception 2000;62:297-303
213. Baird DT. Medical abortion in the first trimester. Best Pract Res Clin Obstet Gynaecol 2002;16:221-36
214. Ashok PW, Flett GM, Templeton A. Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol. Lancet 1998;352:542-3
215. Thong KJ, Baird DT. A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second-trimester pregnancy. Contraception 1992;46:11-16
216. Ho PC, Chan YF, Lau W. Misoprostol is as effective as gemeprost in termination of second-trimester pregnancy when combined with mifepristone: a randomised comparative trial. Contraception 1996;53:281-3
217. Tang OS, Ho PC. Medical abortions in the second trimester. Baillieres Clin Obstet Gynaecol 2002;16:237-46
218. Ho PC, Ngai SW, Liu KL. Vaginal misoprostol compared with oral misoprostol for termination of second-trimester pregnancy. Obstet Gynecol 1997;90:735-8
219. El-Refaey H, Templeton AA. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone. Hum Reprod 1995;10:475-8
220. UK Multicentre Study Group. Oral mifepristone 600 mg and vaginal gemeprost for mid-trimester induction of abortion. Contraception 1997;56:361-6
221. Le Roux PA, Pahal GX, Hoffman L, et al. Second-trimester termination of pregnancy for fetal anomaly or death. Eur J Obstet Gynecol Reprod Biol 1999;95:52-4
222. Wagaarachchi PT, Ashok PW, Narvekar NN, et al. Medical management of late intrauterine death using a combination of mifepristone and misoprostol. Br J Obstet Gynaecol 2002;109:443-7
223. Royal College of Obstetricians and Gynaecologists. Induced Abortion. Guideline No. 11. London: Royal College of Obstetricians and Gynecologists, 1997
224. Royal College of Obstetricians and Gynaecologists. Care of Women Requesting Induced Abortion. London: Royal College of Obstetricians and Gynecologists, 2000
225. Regelson W, Loria R, Kalimi M. Beyond 'abortion'. RU-486 and the needs of the crisis constituency. J Am Med Assoc 1990;264:1026-7
226. Radestad A, Christensen NJ, Stromberg L. Induced cervical ripening with mifepristone in first-trimester abortion: a double-blind randomised biomechanical study. Contraception 1988;8:301-12
227. Urquhart DR, Templeton AA. Mifepristone for cervical priming prior to surgically induced abortion in the late first trimester. Contraception 1990;42:191-9
228. Asch RH, Weckstein LN, Balmaceda JC, et al. Non-surgical expulsion of non-viable early pregnancy: a new application of RU 486. Hum Reprod 1990;5:481-3
229. El-Refaey H, Hinshaw K, Henshaw R, et al. Medical management of missed abortion and anembryonic pregnancy. Br Med J 1992;305:1399
230. Wagaarachchi PT, Ashok PW, Narvekar NN, et al. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum Reprod 2001;16: 1849-53
231. Machtinger R, Stockheim D, Goldenberg M, et al. A randomized prospective study of misoprostol alone or combined with mifepristone for treatment of first-trimester spontaneous abortion. Fertil Steril 2002;78(Suppl. 1):S64
232. Lelaidier C, Baton Saint Mleux C, Fernandez H, et al. Mifepristone (RU 486) induces embryo expulsion in first-trimester non-developing pregnancies: a prospective randomized trial. Hum Reprod 1993;8:492-5
233. Nielsen S, Hahlin M, Platz-Christensen J. Randomised trial comparing expectant with medical management for first-trimester miscarriages. Br J Obstet Gynaecol 1999:106:804-7
234. Gazvani MR, Baruah DN, Alfirevic Z, et al. Mifepristone in combination with methotrexate for the medical treatment of tubal pregnancy: a randomized, controlled trial. Hum Reprod 1998;13:1987-90
235. Perdu M, Camus E, Rozenberg P, et al. Treating ectopic pregnancy with the combination of mifepristone and methotrexate: a phase II nonrandomized study. Am J Obstet Gynecol 1998;179:640-43
236. Cingotti M, Moxhon E, Gandour A. Treatment of extrauterine pregnancy with RU 486. A case report. Rev Fr Gynecol Obstet 1990;85:631-3.
237. Hajenius PJ, Engelsbel S, Mol BWJ, et al. Randomised trial of systemic methotrexate versus laparoscopic salpingostomy in tubal pregnancy. Lancet 1997;350:774-9
238. Liu F, Zhang H, Liu Y, et al. Mifepristone in the treatment of 47 ectopic pregnancy patients. Hunan Yi Ke Da Xue Xue Bao 1998;23:265-8
239. Zhang W, Wang L. Mifepristone in treating ectopic pregnancy. Chin Med J (Engl) 1999;112:376-8
240. Levin JH, Lacarra M, d'Ablaing G, et al. Mifepristone (RU 486) failure in an ovarian heterotopic pregnancy. Am J Obstet Gynecol 1990;163:543-4
241. Murphy AA, Kettel LM, Morales AJ, et al. Endometrial effects of long-term low-dose administration of RU486. Fertil Steril 1995;63:761-6
242. Kettel LM, Murphy AA, Mortola JF, et al. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril 1991;56:402-7
243. Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-8
244. Kettel LM, Murphy AA, Morales AJ, et al. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178:1151-6
245. American College of Obstetricians and Gynecologists. Uterine Leiomyomata. ACOG Technical Bulletin No. 192. Washington, DC: American College of Obstetricians and Gynecologists, 1994:1
246. Murphy AA, Morales AJ, Kettle LM, et al. Regression of uterine leiomyoma to the antiprogesterone RU 486: dose-response effect. Fertil Steril 1995;64:187-90
247. Yang Y, Zheng S, Li K. Treatment of uterine leiomyoma by two different doses of mifepristone. Chin J Obstet Gynecol 1996;31:624-6
248. Zeng C, Gu M, Huang H. A clinical control study on the treatment of uterine leiomyoma with gonadotrophin-releasing hormone agonists or mifepristone. Zhonghua Fe Chan Ke Zu Zhi 1998;33:490-2
249. Eisinger SH, Meldrum S, Fiscella K, et al. Low-dose mifepristone for uterine leiomyoma. Obstet Gynecol 2003;101:243-50
250. Horwitz KB. The antiprogestin RU38486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-sensitive T47D10 human breast cancer cells. Endocrinology 1985;116:2236-45
251. Bardon S, Vignon F, Chalbos D, et al. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J Clin Endocrinol Metab 1985;60:692-7
252. Bardon S, Vignon E, Montcourrier P, et al. Steroid receptor-mediated cytotoxicity of an antiestrogen and an anti-progestin in breast cancer cells. Cancer Res 1987;47:1441-8
253. Klijn JGM, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000;65:825-30
254. El Etreby MF, Liang Y, Wrenn RW, et al. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1998;51:149-68
255. Michna H, Schneider MR, Nishino Y, et al. The antitumor mechanism of progesterone antagonists is a receptor-mediated anti-proliferative effect by induction of terminal cell death. J Steroid Biochem 1989;34:447-53
256. Musgrove EA, Lee CSL, Cornish AL, et al. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor. Mol Endocrinol 1997;11:54-66
257. Hackenberg R, Hannig K, Beck S, et al. Androgen-like and anti-androgen-like effects of anti-progestins in human mammary cancer cells. Eur J Cancer 1996;32:696-701
258. Hyder SM, Murthy L, Stancel, GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998;58:392-5
259. Schneider MR, Michna H, Nishino Y, et al. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Mol Biol 1990;37:783-7
260. Perrault D, Eisenhauer EA, Pritchard KI. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1996;14:2709-12
261. Klijn JGM, De Jong FH, Bakker GH, et al. Antiprogestins: a new form of endocrine therapy for breast cancer. Cancer Res 1989;49:2851-6
262. Romieux G, Maudelonde T, Ulmann A. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer (Paris) 1987;74:455-9
263. Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985;61:536-40
264. Bertagna X, Bertagna C, Laudat MH, et al. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 1986;63:639-43
265. Chu JW, Matthias DF, Belanoff J, et al. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 2001;86:3568-73
266. Sartor O, Cutler GB Jr. Mifepristone: treatment of Cushing's syndrome. Clin Obstet Gynecol 1996;39:506-10
267. Newfield RS, Spitz IM, Isaacson C, et al. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol 2000; 54:399-404
268. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of un-resectable meningiomas with anti-progesterone mifepristone. J Neurosurg 1991;74:861-6
269. Grunberg SM. The role of antiprogestational therapy for meningiomas. Hum Reprod 1994;9(Suppl. 1):202-7
270. Haak HR, de Keizer RJ, Hagenouw-Taal JC, et al. Successful mifepristone treatment for recurrent, inoperable meningioma. Lancet 1991;11:124-5
271. Blankenstein MA, Verheijen FM, Jacobs JM, et al. Occurrence, regulation and significance of progesterone receptors in human meningioma. Steroids 2000;65: 795-800
272. Phillips CI, Peat K, Gore SM. Topical dexamethasone lowers rabbit ocular tension, as does topical mifepristone, a peripheral blocker of dexamethasone and progesterone. Ophthalmic Res 1989;21:235-8
273. Messinis IE, Krishnan M, Kazem R, et al. Effect of mifepristone on folliculogenesis in women treated with recombinant FSH. Clin Endocrinol 1997;46:309-14
274. Messinis IE, Templeton AA. The effect of the antiprogestin mifepristone (RU 486) on maturation and in-vitro fertilization of human oocytes. Br J Obstet Gynaecol 1988;95:592-5
275. Paulson RJ, Sauer MV, Lobo RA. Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: a hypothesis. Fertil Steril 1997;67:321-5
276. Gnoth C, Halbe E, Freundl G. Persistent ascites after ovarian hyperstimulation syndrome and administration of mifepristone for the termination of pregnancy. Arch Gynecol Obstet 2003;268:65-8
277. Barengolts EI, Lathon PV, Lindh FG. Progesterone antagonist RU 486 has bone-sparing effects in ovariectomized rats. Bone 1995;17:21-5
278. Grow DR, Williams RF, Hsiu JG, et al. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab 1996;81:1933-9
279. Fraser IS. Progesterone-only contraception. In Glasier AF, Gebbie A, eds. Handbook of Family Planning and Reproductive Healthcare. Edinburgh: Churchill Livingstone, 2000:77-103
280. Nicosia AF, Dutton C, Lu J, et al. A prospective, randomized, placebo-controlled trial of mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone (DMPA). Fertil Steril 2002; 78(Suppl. 1):S25-6
281. Cheng L, Zhu H, Wang A, et al. Once-a-month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000;15:1969-72
282. Glasier A, Wang H, Davie J, et al. Administration of an antiprogesterone up-regulates estrogen receptors in the endometrium of women using Norplant™: a pilot study. Fertil Steril 2002;77:366-72
283. Schatzberg AF, Belanoff JJ, Murphy G Jr. Recent research on pharmacogenetics in geriatric depression and mifepristone in delusional depression. J Clin Psychiatry 2002; 63 (Suppl. 1): 108-9
284. Belanoff JK, Rothschild AJ, Cassdy F, et al. An open-label trial of mifepristone for psychotic major depression. Biol Psychiatry 2002;52:386-92
285. Wolkowitz OM, Reus VI. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999;61:698-711
286. Schatzberg AF. New approaches to managing psychotic depression. J Clin Psychiatry 2003;64 (Suppl. 1): 19-23
287. Belanoff JK, Jurik J, Schatzberg LD, et al. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J Mol Neurosci 2002;19:201-6
288. Spitz IM, Robbins A. Antiprogestins in clinical practice. In Sitruk-Ware R, Mishell DR, eds. Progestins and Antiprogestins in Clinical Practice. New York: Marcel Dekker, Inc., 1999:377-90
289. Baird DT. Antigestogens: the holy grail of contraception. Reprod Fertil Dev 2001;13:723-8